VIGIL NEUROSCIENCE
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
VIGIL NEUROSCIENCE
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vigilneuro.com
Total Employee:
51+
Status:
Active
Contact:
857-254-4445
Email Addresses:
[email protected]
Total Funding:
180 M USD
Technology used in webpage:
Google Maps Font Awesome Mobile Non Scaleable Content CrUX Top 50m Amazon Virginia Region ASP.NET IIS IIS 10 COVID-19 Amazon SSL
Similar Organizations
Avidity Biosciences
Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.
Azitra
Azitra is a clinical-stage medical dermatology company developing microbiome-based novel therapeutics to treat skin conditions and diseases.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Capra Biosciences
Capra Biosciences is a biotechnology company harnessing biology for efficient and low-carbon production of everyday chemicals.
Caribou Biosciences
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellares
Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
IDEAYA Biosciences
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sanofi
Sanofi investment in Post-IPO Equity - Vigil Neuroscience
Logos Capital
Logos Capital investment in Series B - Vigil Neuroscience
Vida Ventures
Vida Ventures investment in Series B - Vigil Neuroscience
Atlas Venture
Atlas Venture investment in Series B - Vigil Neuroscience
Invus
Invus investment in Series B - Vigil Neuroscience
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Vigil Neuroscience
Northpond Ventures
Northpond Ventures investment in Series B - Vigil Neuroscience
Rock Springs Capital
Rock Springs Capital investment in Series B - Vigil Neuroscience
Deep Track Capital
Deep Track Capital investment in Series B - Vigil Neuroscience
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Vigil Neuroscience
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-20 | Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.vigilneuro.com Semrush global rank: 3.53 M Semrush visits lastest month: 3.68 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Vigil Neuroscience"
Vigil Neuro
Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells. We are harnessing the tools of …See details»
TEAM - Vigil Neuro
We are a patient-focused, collaborative and passionate team of trailblazers, innovators, and creative thinkers dedicated to realizing the potential of microglia biology and delivering life …See details»
PATIENTS — Vigil Neuro
We are engaging and collaborating with patient communities, caregivers, and advocacy groups to understand their needs to inform our research and to raise awareness. We strive to alleviate the burden and to improve the lives for those …See details»
Vigil Neuroscience - Crunchbase Company Profile
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases. View contacts for Vigil Neuroscience to access new leads and connect with decision-makers.See details»
Vigil Neuroscience - Overview, News & Similar companies
May 7, 2024 · Vigil Neuroscience contact info: Phone number: (857) 254-4445 Website: www.vigilneuro.com What does Vigil Neuroscience do? We are a microglia-focused company …See details»
Vigil Neuroscience Announces First Participant Dosed in Phase 1 ...
Oct 17, 2023 · Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the …See details»
Vigil Neuroscience Strengthens Board of Directors with …
Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of …See details»
David Gray - Chief Science Officer at Vigil Neuro - The Org
Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases. Gray joins Vigil from Inscopix, Inc., where he led the …See details»
Vigil Neuroscience Launches with $50 Million in ... - Business Wire
Dec 8, 2020 · Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the …See details»
STRATEGY - Vigil Neuro
Our strategy is to first develop novel drug candidates for genetically defined patient sub-populations. Our longer-term goal is to develop therapeutics for larger patient populations, …See details»
Vigil Neuroscience Receives Positive Opinion from European …
Sep 26, 2023 · VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with …See details»
Vigil Neuroscience Completes $90 million Series B Financing to …
Aug 18, 2021 · Vigil Neuroscience is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel …See details»
Vigil Neuroscience Announces $40 Million Strategic
Jun 27, 2024 · Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the …See details»
Vigil Neuroscience Announces First Participant Dosed in Phase 1 ...
Oct 17, 2023 · VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with …See details»
Vigil Neuroscience Announces $40 Million Strategic Investment …
Jun 27, 2024 · Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the …See details»
Publications - Vigil Neuro
Design of a Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG-3927) in …See details»
Vigil Neuroscience to Present at Cantor Global Healthcare …
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, …See details»
Vigil Neuroscience Announces Closing of Initial Public Offering
CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia …See details»
Vigil Presents Data on its Small Molecule TREM2 Agonist Program …
Jul 30, 2024 · According to the World Health Organization, AD is the most common type of dementia, and we believe VG-3927 has the potential to offer a differentiated approach to …See details»
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in …
Apr 17, 2024 · Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the …See details»